Aakaar Medical Makes NSE Emerge Debut After 2.28x Subscribed IPO

Aakaar Medical Technologies Limited officially listed on the NSE Emerge platform today, June 27, following a ₹27 crore IPO that drew solid investor interest. The stock opened at ₹75, a 4% premium over its issue price of ₹72, before dipping slightly in early trade.

 

Key highlights:

 

- The IPO was entirely a fresh issue of 37.5 lakh shares, with no offer-for-sale component.

- It was subscribed 2.28 times overall, with strong demand from QIBs (3.51x), retail investors (1.93x), and NIIs (1.48x).

- The company raised ₹7.68 crore from anchor investors ahead of the issue.

- Funds will be used primarily for working capital needs and general corporate purposes.

 

Founded in 2013, Mumbai-based Aakaar Medical specializes in aesthetic healthcare products and devices. Its portfolio includes dermatology and cosmetic solutions sourced both domestically and from countries like South Korea, Spain, and Austria. The company serves dermatologists, plastic surgeons, and aesthetic physicians across 15 Indian states.

 

Financially, Aakaar has shown strong growth. Revenue rose from ₹32.88 crore in FY23 to ₹61.76 crore in FY25, while net profit jumped from ₹2.15 crore to ₹6.04 crore over the same period. The company’s return on equity stands at an impressive 33.81%.

 

Outlook: With a growing footprint in the aesthetic medical space and a healthy balance sheet, Aakaar Medical’s listing marks a promising step forward. Investors will now watch how the company scales its operations and sustains profitability in a competitive market.

 

Sources: Moneycontrol, LiveMint, Economic Times